PDCD1 and cancer: The prospect of SPHK1/MMP1 knockdown combined with the anti-PD-1 therapeutic regimen represents an efficacious approach to enhance T cell-mediated anti-tumor immunity, offering a promising avenue for potential advancements in cancer therapy.